Key result
Insulin ± heparin therapy showed no statistically significant difference compared to plasmapheresis in reducing triglyceride levels in patients with hypertriglyceridemia-induced acute pancreatitis.
Why the study?
Hypertriglyceridemia is a common cause of acute pancreatitis, prompting a comparison of the effectiveness and adverse events of insulin therapy versus plasmapheresis for reducing triglyceride levels.
Does insulin therapy with or without heparin reduce triglyceride levels compared to plasmapheresis in patients with hypertriglyceridemia-induced acute pancreatitis?
Meta-Analysis (n=269)
Does insulin therapy with or without heparin reduce triglyceride levels compared to plasmapheresis in patients with hypertriglyceridemia-induced acute pancreatitis?
Standardized Mean Difference: -0.37 (95% CI -0.99–0.25)
p-value: p=0.25
Insulin therapy with or without heparin is non-inferior to plasmapheresis for reducing triglyceride levels and mortality in hypertriglyceridemia-induced acute pancreatitis.
Similar efficacy and safety between approaches support individualized therapy now; leaves open need for larger RCTs to guide selection.
Background: Hypertriglyceridemia is a common cause of acute pancreatitis (AP). This literature review compared the effectiveness and adverse events of insulin therapy, with or without heparin, and plasmapheresis, in reducing triglyceride levels in patients with hypertriglyceridemia-induced AP. Methods: Systematic reviews, meta-analyses, evidence syntheses, editorials, commentaries, protocols, abstracts, theses and preprints were excluded. Review Manager was used to conduct the meta-analysis. The literature search yielded 2765 articles, but only 5 were included in the systematic review and meta-analysis and the total number of participants in the review was 269. Results: From this study's analysis, insulin ± heparin was more successful in reducing triglyceride levels than plasmapheresis (standardized mean difference -0.37, 95% confidence interval [CI] 0.99 to 0.25; P=0.25). Insulin ± heparin therapy had a lower mortality rate than plasmapheresis (risk ratio [RR] 0.70, 95%CI 0.25-1.95). Hypotension, hypoglycemia, and acute renal failure were less common in the plasmapheresis therapy group than in insulin ± heparin therapy (RR 1.13, 95%CI 0.46-2.81, RR 3.90, 95%CI 0.45-33.78, and RR 0.48, 95%CI 0.02-13.98 for hypotension, hypoglycemia, and acute renal failure, respectively). Conclusions: This study found no significant difference in mortality between insulin ± heparin therapy and plasmapheresis used for the reduction in triglyceride levels. It is notable that no substantial differences were observed in the most common side-effects encountered during these therapies, thus indicating non-inferiority.
No takes yet. Share an insight, caveat, or question.
Shobhit Piplani (2023) conducted a meta-analysis in Hypertriglyceridemia-induced acute pancreatitis (n=269). Insulin ± heparin vs. Plasmapheresis was evaluated on Reduction in triglyceride levels (SMD -0.37, 95% CI -0.99 to 0.25, p=0.25). Insulin ± heparin therapy showed no statistically significant difference compared to plasmapheresis in reducing triglyceride levels in patients with hypertriglyceridemia-induced acute pancreatitis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: